---
id: 055
title: Daptomycin Mechanism and Spectrum
category: antimicrobials
subcategory: daptomycin
tags: [daptomycin, MRSA, VRE, bacteremia, calcium-dependent, lipopeptide]
difficulty: medium
---

## Question

What is daptomycin's mechanism of action and spectrum? Use the **"DAPTO = Ca²⁺-MEMBRANE Killer"** mnemonic.

## Answer

### **"DAPTO = Ca²⁺-MEMBRANE Killer" Mnemonic:**

**Daptomycin requires Calcium to kill via Membrane disruption:**
- **D**isrupts cell membrane
- **A**bsolutely requires Ca²⁺ (calcium-dependent)
- **P**otent bactericidal (rapid killing)
- **T**argets Gram-positives only
- **O**ligomerization → membrane pores

**Ca²⁺-MEMBRANE:**
- **Ca**lcium binding required
- **M**embrane depolarization
- **E**xit of K⁺ ions (cell death)
- **M**ust add calcium to culture media
- **B**actericidal (not static)
- **R**apid killing (faster than vanc)
- **A**ntibiotic of choice for resistant bugs
- **N**o cross-resistance
- **E**xcellent for bacteremia/endocarditis

### **Mechanism of Action:**

**Step 1: Calcium-Dependent Binding**
- Daptomycin binds **10 Ca²⁺ ions** → conformational change
- Inserts lipophilic tail into **bacterial cell membrane**

**Step 2: Oligomerization**
- Forms oligomeric channels in membrane

**Step 3: Membrane Disruption**
- K⁺ efflux → rapid **depolarization**
- Loss of membrane potential
- Cell death (**bactericidal**)

**Unique Feature:** More rapidly bactericidal than vancomycin in vitro

### **Spectrum of Activity:**

| Organism | Activity | Notes |
|----------|----------|-------|
| **MRSA** | Excellent | Bacteremia, endocarditis |
| **MSSA** | Excellent | Alternative to β-lactams |
| **VRE** | Excellent | *E. faecalis*, *E. faecium* |
| **VISA/VRSA** | Excellent | Vancomycin-intermediate/resistant |
| ***S. pneumoniae*** | Good | Including pen-resistant |
| ***S. pyogenes* (GAS)** | Excellent | Skin/soft tissue |
| **Coag-negative staph** | Excellent | Line infections |
| **Enterococcus** (VSE) | Excellent | Alternative to ampicillin |
| **Gram-negatives** | **NO** | No activity |
| **Anaerobes** | Variable | Not primary indication |

## Key Points

### **FDA-Approved Indications:**
1. **Complicated skin/soft tissue infections (cSSTI)** - 4mg/kg IV daily
2. ***S. aureus* bloodstream infections (bacteremia)** - **6-10 mg/kg IV daily**
3. **Right-sided endocarditis** - **6-10 mg/kg IV daily**

**NOT approved for:**
- Left-sided endocarditis (clinical trial failures)
- Pneumonia (inactivated by pulmonary surfactant)

### **Dosing by Indication:**

| Indication | Dose | Duration |
|------------|------|----------|
| **cSSTI** | 4 mg/kg IV daily | 7-14 days |
| **Bacteremia** | **6-10 mg/kg IV daily** | ≥14 days |
| **Right-sided endocarditis** | **6-10 mg/kg IV daily** | 4-6 weeks |
| **Osteomyelitis (off-label)** | 6-10 mg/kg IV daily | 6-12 weeks |

**High-Dose Daptomycin (8-10 mg/kg):**
- Used for persistent MRSA bacteremia
- May shorten time to blood culture clearance
- 2024 evidence: High-dose (8-10 mg/kg) shortens time to sterilization by median 2 days

### **Pharmacokinetics:**

| Parameter | Value | Clinical Implication |
|-----------|-------|---------------------|
| **Bioavailability** | IV only | No PO formulation |
| **Protein binding** | 92% | High |
| **Half-life** | 8 hours | Once-daily dosing |
| **Elimination** | Renal (78%) | Adjust in CrCl <30 |
| **Tissue penetration** | Bone: excellent | Good for osteomyelitis |
| **CSF penetration** | Poor | Not for meningitis |

### **Advantages Over Vancomycin:**
1. **Once-daily dosing** (vs continuous infusion or TID/QID)
2. **No need for drug level monitoring**
3. **More rapid bactericidal activity**
4. **No nephrotoxicity** (vs vanc)
5. **Effective for VISA/VRSA** (vanc-resistant strains)

## Sources

- [StatPearls NBK470407: Daptomycin]
- [NEJM 2006: Daptomycin vs Standard Therapy for SAB and Endocarditis]
- [PMC2374935: Daptomycin Role in MRSA Bacteremia and Endocarditis]

## Media

N/A
